Drug intelligence / Profile preview

Dietzia C79793-74

Development stage: Unknown
Lead developer: Sydney Centre for Digestive Diseases
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Dietzia C79793-74 is a live biotherapeutic product (LBP) consisting of the bacterial strain *Dietzia natronolimnaea* C79793-74. It is being developed by the Centre for Digestive Diseases, led by Dr. Thomas Borody, as a potential treatment for moderate to severe Crohn's disease. The therapeutic rationale is based on the "MAP hypothesis," which suggests that *Mycobacterium avium* subspecies *paratuberculosis* (MAP) plays a causative role in Crohn's disease. Dietzia C79793-74 acts by inhibiting or outcompeting MAP, a mechanism first observed in the treatment of Johne's disease in cattle. In human clinical evaluation, it has been studied in Phase 1/2 open-label trials to assess safety, tolerability, and clinical response.

Other names: Dietzia natronolimnaea C79793-74Dietzia natronolimnaea strain C79793-74

Beyond the preview

Go deeper on Dietzia C79793-74.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dietzia C79793-74.

Explore the full profile